Huart J J, Jouet J P, Bauters F, Goudemand M
Nouv Rev Fr Hematol (1978). 1983;25(4):229-33.
Transfusional therapy regimens have been investigated in a series of 385 patients treated for acute leukemia (AL). During remission induction, fatal hemorrhages occurred in 0.7% of the patients whereas, during the same time, deaths due to infections were four times more frequent. Platelet concentrates (PC) were usually given on the basis of clinical indications. When the risk of hemorrhage was especially high, as during the induction phase of acute promyelocytic leukemia, prophylactic platelet transfusions seemed to be necessary. Alloimmunization developed in 17% to 52% of the patients depending on their cytologic type and in these cases, PC prepared from single donors had to be used. Among the 57 patients with aplastic anemia (AA), bone marrow transplantation was indicated in 17, and 5 of the 10 grafted patients died from hemorrhages. In AA, as the risk of sensitization to platelet alloantigens was higher, PC prepared from single donors were systematically preferred to standard PC. If bone marrow transplantation was planned, PC from histocompatible donors were ordered.
在一系列385例接受急性白血病(AL)治疗的患者中,对输血治疗方案进行了研究。在缓解诱导期,0.7%的患者发生致命性出血,而在同一时期,因感染导致的死亡频率是前者的四倍。血小板浓缩物(PC)通常根据临床指征给予。当出血风险特别高时,如在急性早幼粒细胞白血病的诱导期,预防性血小板输注似乎是必要的。根据细胞类型不同,17%至52%的患者发生了同种免疫,在这些情况下,必须使用单供者制备的PC。在57例再生障碍性贫血(AA)患者中,17例适合进行骨髓移植,10例移植患者中有5例死于出血。在AA中,由于对血小板同种抗原致敏的风险较高,系统地优先选择单供者制备的PC,而不是标准PC。如果计划进行骨髓移植,则订购来自组织相容性供者的PC。